Investigational Drug Details
| Drug ID: | D124 |
| Drug Name: | EPA-E |
| Synonyms: | -- |
| Type: | Chemical drug |
| DrugBank ID: | -- |
| DrugBank Description: | -- |
| PubChem ID: | 9831415 |
| CasNo: | 73310-10-8 |
| Repositioning for NAFLD: | No |
| SMILES: | C(CCCCCCCCCCCCCCC)CCCC(=O)OCC |
| Structure: |
|
| InChiKey: | YBKSMWBLSBAFBQ-UHFFFAOYSA-N |
| Molecular Weight: | 340.592 |
| DrugBank Targets: | -- |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | DGAT1 inhibitor; PLA2 inhibitor |
| Therapeutic Category: | Antiinflammatory agent; Neuroprotective drug |
| Clinical Trial Progress: | Phase 2 completed (In a phase 2 trial, EPA-E had no significant effect on the histologic features of NASH. EPA-E reduced subjects' levels of triglyceride compared with placebo, without any increase in serious adverse events. Clinicaltrials.gov Number: 01154985.) |
| Latest Progress: | Failed in clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0280 | NCT01154985 | Phase 2 | Completed | Has Results | June 2010 | November 20, 2014 | Details |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A12274 | 30538803 | Oxid Med Cell Longev | Dietary DHA/EPA Ratio Changes Fatty Acid Composition and Attenuates Diet-Induced Accumulation of Lipid in the Liver of ApoE-/- Mice. | Details |
| A13161 | 30109054 | R Soc Open Sci | Synergistic effect of eicosapentaenoic acid-enriched phospholipids and sea cucumber saponin on orotic acid-induced non-alcoholic fatty liver disease in rats. | Details |
| A22104 | 24818764 | Gastroenterology | No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. | Details |
| A26238 | 20848203 | Dig Dis Sci | Eicosapentaenoic acid attenuates progression of hepatic fibrosis with inhibition of reactive oxygen species production in rats fed methionine- and choline-deficient diet. | Details |
| A35710 | 19856102 | Dig Dis Sci | Highly purified eicosapentaenoic acid ethyl ester prevents development of steatosis and hepatic fibrosis in rats. | Details |